- Mass drug administration to reduce malaria incidence in a low-to-moderate 1
- endemic setting: short-term impact results from a cluster randomised 2
- controlled trial in Senegal 3
- 4 **Authors:**
- El-hadji Ba Konko Ciré, PhD<sup>1\*</sup>, Michelle E. Roh, PhD<sup>2,3\*</sup>, Abdoulaye Diallo, MD<sup>1</sup>, Tidiane 5
- Gadiaga, MD<sup>4</sup>, Amadou Seck, MS<sup>1</sup>, Sylla Thiam, MD<sup>1</sup>, Seynabou Gaye, MD<sup>5</sup>, Ibrahima Diallo, 6
- PharmD<sup>5</sup>, Aminata Colle Lo, PhD<sup>1</sup>, Elhadji Diouf, MPH<sup>1</sup>, Omar Gallo Ba, MD<sup>1</sup>, Alioune Badara 7
- Gueye, MD<sup>6</sup>, Ari Fogelson, MSc<sup>7</sup>, Xue Wu, MMed<sup>2,3</sup>, Prof Paul Milligan, PhD<sup>7</sup>, Tabitha Kibuka, MPH<sup>2</sup>, Moustapha Hama, MHA<sup>2</sup>, Erin Eckert, PhD<sup>2</sup>, Julie Thwing, MD<sup>8</sup>, Adam Bennett, PhD<sup>2,9</sup>, 8
- 9
- Prof Roly Gosling, MD<sup>2,3,10</sup>, Jimee Hwang, MD<sup>11,12</sup>, Doudou Sene, MD<sup>5</sup>, Fatou Ba, PhD<sup>5</sup>, Bayal Cissé, MD<sup>4</sup>, Katharine Sturm-Ramirez, PhD<sup>13</sup>, Michelle S. Hsiang, MD<sup>2,3†</sup>, Prof Jean Louis 10
- 11
- Ndiave, MD<sup>1†</sup> 12

#### **Author Affiliations:** 13

- <sup>1</sup> Université Iba Der Thiam de Thiès, Thiès, Senegal 14
- <sup>2</sup> US President's Malaria Initiative Impact Malaria, Washington DC, USA 15
- <sup>3</sup> Institute for Global Health Sciences, University of California, San Francisco, USA 16
- <sup>4</sup> District of Tambacounda, Ministry of Health and Social Action, Tambacounda, Senegal 17
- 18 <sup>5</sup> Senegal National Malaria Control Programme, Ministry of Health and Social Action, Dakar,
- Senegal 19
- <sup>6</sup> US President's Malaria Initiative, United States Agency for International Development, Dakar, 20
- 21
- <sup>7</sup> Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical 22
- 23 Medicine, London, UK
- <sup>8</sup> Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA 24
- <sup>9</sup> PATH, Seattle, Washington, USA 25
- <sup>10</sup> Department of Disease Control, London School of Hygiene and Tropical Medicine, London 26
- 27
- <sup>11</sup> US President's Malaria Initiative, Malaria Branch, US Centers for Disease Control and 28
- 29 Prevention, Atlanta, Georgia, USA
- <sup>12</sup> United States Public Health Service, Rockville, MD, USA 30
- <sup>13</sup> US President's Malaria Initiative, Malaria Branch, US Centers for Disease Control and 31
- 32 Prevention, Dakar, Senegal, USA
- \*Contributed equally 33
- <sup>†</sup>Contributed equally 34

#### 35 **Corresponding authors:**

Michelle E. Roh UCSF Institute for Global Health Sciences

550 16th Street, 3rd Floor San Francisco, CA 94158, USA

Email: michelle.roh@ucsf.edu

El-hadji Konko Ciré Ba

Université Iba Der Thiam de Thiès

Grand Standing, Thiès BP: A967 Thiès

Email: el-hadj.ba@ird.fr

# Summary

#### 37 **Background**

36

- 38 In Africa, the scale-up of malaria control interventions, including seasonal malaria
- 39 chemoprevention (SMC), has dramatically reduced malaria burden, but progress toward malaria
- 40 elimination has stalled. We evaluated mass drug administration (MDA) as a strategy to
- 41 accelerate reductions in malaria incidence in Senegal.

#### 42 Methods

- We conducted an open-label, cluster-randomised controlled trial in a low-to-moderate
- 44 transmission setting of Tambacounda, Senegal. Eligible villages had a population size between
- 45 200–800. All villages received pyrethroid-piperonyl butoxide bednets and proactive community
- case management of malaria at baseline. Sixty villages were randomised 1:1 to either three
- 47 cycles of MDA with dihydroartemisinin-piperaquine+single-low dose primaquine administered
- to individuals aged  $\ge 3$  months, six-weeks apart starting the third week of June (intervention), or
- 49 standard-of-care, which included three monthly cycles of SMC with sulfadoxine-
- 50 pyrimethamine+amodiaguine administered to children aged 3–120 months starting end of July
- 51 (control). MDA and SMC were delivered door-to-door. The primary outcome was clinical
- 52 malaria incidence in all ages assessed during the peak transmission season (July-December), the
- year after intervention. Here, we report safety, coverage, and impact outcomes during the
- intervention year. The trial is registered at ClinicalTrials.Gov (NCT04864444).

# 55 Findings

- 56 Between June 21, 2021 and October 3, 2021, 6505, 7125, and 7250 participants were
- administered MDA and 3202, 3174, and 3146 participants were administered SMC across
- 58 cycles. Coverage of ≥1 dose of MDA drugs was 79%, 82%, and 83% across cycles. During the
- transmission season of the intervention year, MDA was associated with a 55% [95% CI: 28%–
- 60 72%] lower incidence of malaria compared to control (MDA: 93 cases/1000 population; control:
- 61 173 cases/1000 population). No serious adverse events were reported in either arm.

#### 62 **Interpretation**

- In low-to-moderate malaria transmission settings with scaled-up malaria control interventions,
- MDA with dihydroartemisinin-piperaquine+single-low dose primaquine is effective and well-
- 65 tolerated for reducing malaria incidence. Further analyses will focus on the sustainability of this
- 66 reduction.

#### 67 Funding

68 United States President's Malaria Initiative

#### 69 Keywords

- 70 mass drug administration; seasonal malaria chemoprevention; dihydroartemisinin-piperaquine;
- 71 primaquine; sulfadoxine-pyrimethamine; amodiaquine; Plasmodium falciparum; malaria;
- 72 Senegal; transmission
- 73 **Word Count:** Summary (300); Manuscript (4488)

Research in context

74

75 Evidence before this study 76 The current World Health Organization (WHO) guidelines recommend that malaria programmes 77 consider mass drug administration (MDA) for *Plasmodium falciparum* transmission reduction in 78 low-to-very low transmission settings (broadly defined as parasite prevalence < 10% or annual 79 malaria incidence of <250 cases per population). In moderate-to-high transmission areas, MDA 80 is recommended for rapid reduction of disease burden, but not for transmission reduction due to 81 the lack of published studies demonstrating its short- or long-term benefits. Among the numerous 82 studies that contributed to this recommendation, five evaluated the antimalarial combination, 83 dihydroartemisinin-piperaquine + single low-dose primaquine. However, none of the studies 84 were conducted in countries implementing seasonal malaria chemoprevention as part of their routine malaria control strategy. 85 86 On January 23, 2024, we conducted a PubMed search using the following term: "mass drug 87 administration" AND "dihydroartemisinin-piperaquine". We found one additional cluster 88 randomised controlled trial conducted in a moderate transmission setting of The Gambia (an 89 SMC-implementing country), that evaluated mass drug administration with the antimalarial 90 combination, dihydroartemisinin-piperaquine + ivermectin. This study demonstrated that MDA 91 was associated with a 70% reduction in the odds of PCR-confirmed malaria two months after the 92 last round of MDA. However, given the study demonstrated little evidence on entomological 93 outcomes, authors concluded that much of the observed effect of MDA was likely attributable to 94 the antimalarial efficacy of dihydroartemisinin-piperaquine. 95 Added value of this study 96 Our study adds to the current evidence base demonstrating the benefits of MDA with 97 dihydroartemisinin-piperaquine + single-dose primaquine on malaria burden reduction and may 98 have impacts on short-term transmission. Combined with The Gambia trial results, our study 99 provides new evidence demonstrating that MDA with dihydroartemisinin-piperaquine can have 100 short-term benefits on transmission in low and moderate transmission settings where malaria 101 transmission is highly seasonal. 102 *Implications of all the available evidence* 103 As countries in sub-Sahelian and Sahelian Africa progressively scale-up their malaria control 104 interventions, they will reach a plateau where no further gains can be made. In low and moderate 105 transmission settings, MDA is a well-tolerated and effective intervention for rapidly reducing 106 malaria burden and may have an impact on transmission in the short-term.

### Introduction

107

- 108 Malaria is a major public health concern in Africa. In regions where transmission is highly
- 109 seasonal, seasonal malaria chemoprevention (SMC) has been widely adopted to prevent
- 110 morbidity and mortality in children at-risk of severe malaria. SMC involves the monthly
- administration of sulfadoxine-pyrimethamine + amodiaguine given during the peak transmission 111
- season to treat existing parasitaemia and prevent new infections. Since its initial 112
- recommendation by the World Health Organisation (WHO) in 2012, SMC has expanded to 18 113
- African countries, covering 53 million children in 2023.<sup>2</sup> The scale-up of SMC has been 114
- successful, demonstrating reductions in childhood clinical malaria incidence by 60–88% under 115
- programmatic conditions.<sup>1,3</sup> 116
- 117 Through high coverage of SMC, strong vector control, and prompt case management, countries
- 118 in Sahelian and sub-Sahelian Africa have made significant strides in controlling malaria,
- 119 prompting many to establish new goals for malaria elimination. However, recent progress toward
- elimination has stalled, and elimination has stalled, encessitating enhanced coverage of proven core interventions and the 120
- 121 consideration of new interventions to rapidly reduce transmission. One promising approach is
- 122 mass drug administration (MDA), which involves the administration of antimalarials to all
- 123 individuals in a defined geographic area at a frequency and duration tailored to the local malaria
- epidemiology and goals. For MDA to have an impact on transmission, high coverage  $(\geq 80\%)^{5,6}$ 124
- 125 of the target population is needed, which requires an optimized delivery approach and strong
- community engagement. Achieving high coverage may be less challenging in countries 126
- successfully implementing SMC, as they can leverage their existing infrastructure of door-to-127
- door delivery and community and health system acceptance of chemoprevention.<sup>8,9</sup> 128
- 129 In addition to attaining high coverage, the effectiveness of MDA depends on the type of
- 130 antimalarial regimen used. In *Plasmodium falciparum*-dominant regions, dihydroartemisinin-
- 131 piperaquine is an attractive agent for MDA given its good safety profile, long prophylactic
- period, and relatively low-levels of artemisinin resistance in Africa. 10,11 However, 132
- dihydroartemisinin-piperaquine has no known efficacy against mature gametocytes 12,13—the 133
- 134 parasites responsible for human-to-mosquito transmission. Single low-dose primaquine is a
- gametocytocidal agent shown to be safe and associated with the near complete prevention of 135
- human-to-mosquito transmission. 14,15 It is likely that the combination of these drugs may confer 136
- 137 greater benefits than dihydroartemisinin-piperaquine alone, allowing MDA to have a greater
- impact on transmission. 138
- 139 Here, we present results from a cluster randomised controlled trial assessing the safety, coverage,
- 140 and short-term impact of three cycles of MDA with dihydroartemisinin-piperaquine + single
- 141 low-dose primaguine on *P. falciparum* incidence and prevalence during the intervention year.
- 142 This study aimed to fill a critical evidence gap regarding the effectiveness of MDA to rapidly
- 143 reduce malaria burden in a highly seasonal, low-to-moderate transmission setting where malaria
- 144 control measures have been scaled-up and additional interventions are needed to accelerate
- 145 malaria elimination.

#### **Methods**

Study setting

147

164

- 148 The study was conducted in Tambacounda Health District of southeastern Senegal (Appendix
- 1). The district is comprised of 523 villages with an estimated population size of 297,761 in
- 2020. In southeastern Senegal, malaria transmission is low-to-moderate (50–200 cases per 1000
- population) and highly seasonal, with most cases occurring between July and December. In this
- region, the national malaria programme (*Programme National de Lutte contre le Paludisme*;
- 153 PNLP) implements standard malaria control interventions including routine distribution of
- insecticide-treated nets, malaria case management at health facilities, SMC to children 3–120
- months of age (except those with a severe/chronic illness, known hypersensitivity to SMC drugs,
- and history of antimalarial receipt in the prior three weeks), and proactive community case
- management of fever through the *Prise en Charge à Domicile Plus* (PECADOM+) model. In the
- 158 PECADOM+ model, community health workers, known as dispensateur de soins à domiciles
- 159 (DSDOMs), conduct weekly household visits to identify and treat suspected malaria cases during
- the malaria transmission season. Despite scale-up of these interventions, progress toward
- transitioning these zones to pre-elimination status has been slow. Thus, in these areas, the
- program needs an accelerator intervention to aggressively push the elimination margins and meet
- the national goal to eliminate malaria by 2030.

### Study design and participants

- The study employed a two-arm, open-label, cluster randomised controlled trial design. Sixty
- villages were randomly selected for participation. Villages were eligible if they had a population
- size between 200–800; were located within a health post catchment area with an annual malaria
- incidence of 60–160 cases/1000 population; and had an established PECADOM+ system or the
- 169 PEACDOM+ model was planned for implementation in the village. Villages were selected so
- that village centroids were  $\geq 2.5$  km apart.
- 171 Participant eligibility was assessed prior to each MDA cycle. Residents of intervention villages
- were eligible for MDA if they were  $\geq 3$  months of age and excluded if they reported a
- severe/chronic illness, had a known hypersensitivity to study drugs, were pregnant (confirmed by
- urine test), had taken drugs that could influence cardiac function or prolong QTc interval, or
- received antimalarials in the prior three weeks. Children <2 years of age and breastfeeding
- women were further excluded from receiving single low-dose primaquine. No SMC was
- provided during the intervention year in intervention villages.
- Written informed consent was obtained before the first MDA cycle and cross-sectional surveys.
- Parental written informed consent was obtained from participants <18 years of age and written
- informed assent was obtained from children 13–17 years of age.
- Ethical approval of this trial was granted by the Comité National d'Ethique pour la Recherche en
- Santé (CNERS) of Senegal and the University of California, San Francisco (UCSF) Human
- 183 Research Protection Program. The U.S. Centers for Disease Control and Prevention approved
- reliance on UCSF. The trial was registered with ClinicalTrials.gov (NCT04864444) and
- oversight was provided by an independent data safety monitoring committee and external
- monitor. An interim safety analysis was conducted after the first MDA cycle.

187 Randomisation and masking 188 Study villages were randomised 1:1 to intervention or control. To ensure adequate balance with respect to specified variables, villages were stratified based on whether PECADOM+ was 189 190 present at baseline. Then a constrained randomisation approach was undertaken using the 191 following village-level covariates: health post of village, distance to health post, baseline malaria 192 prevalence (assessed through a survey conducted at the end of the pre-intervention transmission 193 season), village population size, and population size of children <10 years. A study investigator 194 (MER) randomly generated intervention assignment. Participants, field team, and investigators 195 were unblinded to allocation assignment. Laboratory technicians were blinded to intervention 196 assignment. 197 **Procedures** 198 Community mobilisation and sensitisation 199 Upon village selection, the study team held meetings with administrative, health, and religious 200 leaders of Tambacounda Health District to discuss the study aims, planned activities, and receive 201 consent for study implementation. Community sensitisation materials were developed by the 202 study team and implemented by local health staff. In the months prior to MDA, which coincided 203 with the peak COVID-19 pandemic, additional social media campaigns, local community radio 204 announcements, and television advertisements were conducted. Prior to each MDA cycle, town 205 hall meetings and household visits were undertaken to ensure that the community was well-206 informed. 207 Interventions 208 In the control arm, the standard-of-care chemoprevention (which consisted of three cycles of 209 SMC with sulfadoxine-pyrimethamine + amodiaguine) was administered to children aged 3-120 210 months at four-week intervals, initiated at the presumed start of the malaria transmission season. 211 In the intervention arm, three cycles of MDA with dihydroartermisinin-piperaquine + single lowdose primaquine were administered to individuals aged  $\geq 3$  months at six-week intervals. To 212 achieve maximal impact on clearing the infectious reservoir, 16,17 MDA was initiated one month 213 214 prior to the presumed start of the transmission season (Figure 1). Prior to intervention 215 implementation, pyrethroid-piperonyl butoxide (PBO) bednets were distributed door-to-door to 216 all study villages and year-round PECADOM+ was established to monitor malaria incidence. 217 MDA and SMC were delivered door-to-door by DSDOMs via directly observed therapy for all 218 three doses. Study drugs were administered using an age-based dosing strategy per 219 manufacturer's instructions (**Appendix 2**). For each MDA cycle, dihydroartemisinin-piperaquine 220 (Eurartesim<sup>™</sup>, Sigma-Tau, Italy) was given for three consecutive days and single low-dose 221 primaquine (Remedica Ltd, Limassol, Cyprus) was given with the first dose of 222 dihydroartemisinin-piperaquine. For each SMC cycle, amodiaquine (Fosun Pharma, Shanghai, 223 China) was given for three consecutive days and sulfadoxine-pyrimethamine (Fosun Pharma,

Shanghai, China) was given with the first dose of amodiaquine. For participants who were

225 unable to swallow tablets (e.g., young children), tablets were crushed and mixed in water. If the 226 participant vomited within 30 minutes of administration, the full dose was re-administered. If the 227 re-administered dose was vomited within 30-60 minutes, half the dose was administered. 228 During drug administration, individuals with symptomatic malaria confirmed by a histidine-rich 229 protein 2-based rapid diagnostic test (RDT) (ParaHIT®-f, ARKRAY Healthcare Pvt Ltd, Surat, 230 India) were treated with artemether-lumefantrine and did not receive study drugs until the 231 subsequent cycle. 232 Malaria surveillance 233 Malaria cases were captured through health facility and PECADOM+ registries. Suspected cases 234 (i.e., presentation of fever or history of fever in the past 48 hours) were confirmed by RDT. To 235 ensure high-quality capture of incident cases, PECADOM+ was expanded year-round 236 implementation in all study villages and fully scaled-up by March 1, 2021. Data were collected 237 on paper-based registries and abstracted onto electronic databases. Duplicates between registries 238 were removed. Village-level population size was estimated by averaging estimates from two 239 censuses conducted before-and-after intervention implementation (**Figure 1**). 240 Pharmacovigilance Passive and active pharmacovigilance systems were used to monitor the safety of MDA. For 241 passive surveillance, adverse events (AEs) following drug intake were recorded by study staff or 242 DSDOMs into standardised case report forms. Participants were encouraged to inform local 243 244 health or study staff if they experienced an AE within one month after drug intake. AEs were 245 graded by a study clinician (e.g., mild, moderate, or severe) and managed free of charge. For 246 active surveillance monitoring, the study staff surveyed 220 random households per study arm on 247 the day after the last dose of study drugs. Households were sampled from every village, 248 proportionate to village population size, such that five households were sampled from villages 249 with <300 residents and ten households from villages with ≥300 residents. In intervention 250 villages, the study team randomly sampled three members per household according to their age 251 group: <5, 5–15, and ≥15 years. In control villages, three household members <10 years of age 252 were randomly sampled. Survey participants were asked if they experienced an AE and to 253 describe the event, including type, onset date, and duration. Severity was graded by a study 254 clinician. 255 Cross-sectional surveys 256 To determine parasite prevalence, cross-sectional surveys were conducted at the end of the 257 transmission season before-and-after intervention implementation (December 10-20, 2020 and December 9–21, 2021). A two-stage cluster sampling strategy was undertaken to randomly select 258 259 households and household members from all villages. Participants were asked about their 260 demographic characteristics, malaria prevention measures, and history of fever. Suspected 261 malaria cases were confirmed by RDT and those with a positive test were treated with 262 artemether-lumefantrine. A fingerprick blood sample was taken for microscopy and for dried

blood spots (DBS) to confirm parasitaemia by PCR and to genotype drug resistance markers.

264 Laboratory analysis 265 Microscopy slides and DBS from surveys were transported to Université Iba Der Thiam de 266 Thiès. Slides were stained with 6% Giemsa for 20 min and read by two microscopists. A third 267 reviewer settled discrepant findings. Parasite DNA was extracted from DBS using the Chelex-100 extraction method<sup>18</sup> and tested for parasitemia by real-time PCR using species-specific 268 primers based on 18s rRNA gene as previously described. 19 PCR-positive samples were 269 genotyped to assess the presence of point mutations in the pfK13, pfdhps, pfdhfr, pfcrt, and 270 271 pfmdr1 genes using high-resolution melting analysis as previously described.<sup>20</sup> 272 Study outcomes 273 The primary outcome of the trial was village-level malaria incidence in the year after 274 intervention implementation. Here, we report the impact of MDA on incidence during the 275 transmission season of the implementation year. Village-level malaria incidence was defined as 276 the number of RDT-confirmed symptomatic malaria cases detected through health post and 277 PECADOM+ surveillance divided by the average village population size obtained from two 278 censuses performed before-and-after intervention implementation (Figure 1). Secondary 279 outcomes included parasite prevalence by microscopy and PCR, coverage and safety of MDA, 280 and prevalence of drug resistance markers assessed through cross-sectional surveys. Coverage was defined according to WHO guidelines<sup>7</sup>. For each chemoprevention campaign, a 281 pre-intervention census was used to generate a registry that determined who would be targeted 282 283 for each cycle. Data on adherence and dose were recorded for each person and day. The registry 284 was updated throughout the campaign to identify new residents, deaths, and emigrants. Both 285 crude and distributional coverage are reported. Crude coverage was defined as the proportion of 286 residents who received ≥1 dose of study drugs among study residents. Denominator included 287 absences, refusals, and those who did not meet the eligibility criteria. Distribution coverage was 288 defined as the proportion of residents who received  $\geq 1$  dose among eligible residents, thereby 289 excluding pregnant women and those with a self-reported illness. Both coverage metrics 290 excluded deaths and emigrants. 291 Statistical analysis 292 All analyses were conducted using Stata version 17.0 or R version 4.2.2. Sample size 293 calculations were based on detecting a 50% relative difference in RDT-confirmed malaria 294 incidence between arms in the year post-intervention. We assumed mass distribution of 295 pyrethroid-PBO bednets, SMC, and scale-up of community case management would 296 cumulatively reduce annual malaria incidence by 50% in the control arm from 100 to 50 297 cases/1000 population before-and-after intervention implementation. Based on a coefficient of 298 variation of 0.80 and an average cluster size of 250, a sample size of 60 clusters provided 80% 299 power (using a 5% significance level) to detect a 50% relative difference in the MDA arm 300 (intervention effect) using a two-tailed alpha test.

Analyses were carried out using an intention-to-treat approach. Intervention impact on incidence was assessed using mixed-effects Poisson regression with village-level random intercepts. In the unadjusted model, the following indicator variables were included: a treatment indicator that equalled 1 in intervention villages during the implementation year and 0 otherwise and a time variable that equalled 1 during the implementation year and 0 otherwise. Adjusted analyses included covariates used in the stratified constrained randomization scheme. Intervention impact was defined as the percent reduction in incidence between July and December in the intervention arm compared to the control arm (1–incidence rate ratio (IRR<sub>intervention</sub>)\*100%). Intervention effects on parasite prevalence were estimated using Poisson regression with robust standard errors. Survey weights accounting for number of households and household size were incorporated into prevalence analyses. Prespecified subgroup analyses were conducted by age group (e.g., ≥ or <10 years of age), DSDOM presence at baseline, and baseline transmission intensity (low versus moderate; low defined as parasite prevalence <10% as defined by WHO¹) using two-way interaction terms between treatment and subgroup variables.

# Results

301

302

303

304

305

306

307

308

309

310

311

312

313

314

- 316 Between September 1, 2020 and October 25, 2020, 523 villages in the study area were
- geolocated and screened for eligibility, and 111 met the inclusion criteria (Figure 2). Of these,
- 318 60 villages were randomly selected allowing for a  $\geq$ 2.5 km distance between village centroids
- and randomised to intervention or control. Village-level factors included in the constrained
- randomisation were balanced across arms (**Table 1**). Overall, coverage of pyrethroid-PBO
- bednets was high (98%) and similar between arms. In the pre-intervention year, 81% of children
- 322 <10 years of age reported receiving the most recent cycle of SMC and 71% reported receiving all</p>
- 323 three cycles. Twenty percent reported sleeping away from their home in the past 15 days.
- In the intervention arm, 8931, 9571, and 9703 residents were screened for the first, second, and
- third cycle of the MDA campaign. Distribution coverage of single low-dose primaquine (where
- the denominator excluded ineligible residents) was 79% (6286/7992), 82% (6949/8462), and
- 84% (7199/8575) across the three cycles. Distribution coverage of  $\geq 1$  dose of
- dihydroartemisinin-piperaquine among the eligible individuals was 79% (6505/8229), 82%
- 329 (7125/8673), and 83% (7250/8690) in the first, second, and third cycles. Distribution coverage of
- all three doses of dihydroartemisinin-piperaquine was 74%, 79%, and 81% across cycles.
- 331 Distribution coverage was higher in those <10 years compared to ≥10 years (distribution
- coverage of  $\geq 1$  dose was 85%, 86%, and 87% in <10 years across cycles, and 75%, 80%, and
- 81% in  $\geq$ 10 years across cycles). Crude coverage of  $\geq$ 1 dose of dihydroartemisinin-piperaguine
- was 73%, 74%, and 75% across cycles. By village, distribution coverage ranged from 58%–97%;
- 50%, 67%, and 70% of intervention villages reached the WHO target coverage of  $\geq$ 80% in the
- first, second, and third cycles, respectively (**Appendix 3**). The major reasons for non-
- participation were absence (range: 14%–21%) and illness (range: 5%–7%) (**Appendix 4**).
- Absences were similar between males and females (1·12:1 ratio) and in age to those who
- received MDA (16 years [interquartile range (IQR): 7–26] versus 13 years [IQR: 6–27]).
- Refusals were rare (1%–2%) and mostly among males (70%) with a median age of 22 years
- 341 [IQR: 15–30].

- In the control arm, 3492, 3489, and 3487 children aged 3–120 months were screened for the first,
- second, and third SMC cycle. Distribution coverage of ≥1 dose of SMC drugs was 93%
- 344 (3202/3457), 92% (3174/3442), and 92% (3146/3434) across cycles. Distribution coverage for
- all three SMC doses was 92%, 92%, and 91% across cycles. Crude coverage of ≥1 dose was
- 92%, 91%, and 90% across cycles. By village, distribution coverage ranged from 62%–100%;
- 93% of SMC villages reached ≥80% coverage across all cycles (**Appendix 3**). Major reasons for
- non-receipt of SMC were absence (7%) and illness (1%–2%) (**Appendix 4**). Refusals of SMC
- 349 were low across cycles ( $\leq 1\%$ ).
- During the pre-intervention transmission season (July-December 2020), malaria incidence was
- 181 and 204 cases/1000 population in the intervention and control arms, respectively (**Table 2**).
- In the transmission season of the intervention year (July-December 2021), malaria incidence
- reduced to 93 cases/1000 population in the intervention arm and to 173 cases/1000 population in
- the control arm (**Table 2**; **Figure 3**). The unadjusted intervention effect of MDA was 52% [95%]
- 355 CI: 21%, 71%]. The adjusted intervention effect, which accounted for variables included in the
- constrained randomisation was 55% [95% CI: 28%, 72%].
- Pre-specified subgroup analyses showed evidence of an interaction by age group; the adjusted
- intervention effect was 58% [95% CI: 33%, 74%] in the  $\geq$ 10 years age group and 46% [95% CI:
- 359 10%, 67%] in the <10 years age group (p<sub>interaction</sub>=0.016) (**Table 2; Figure 3**). The impact of
- 360 MDA on malaria incidence was similar in low and moderate transmission settings defined as
- microscopy parasite prevalence of <10% versus ≥10% (adjusted intervention effect=55% [31%,
- 362 71%] versus 52% [-19%, 81%]; p<sub>interaction</sub>=0.88) (**Table 2; Figure 3**).
- By microscopy, parasite prevalence decreased between 2020 and 2021, from 6·1% to 1·8% in the
- intervention arm and from 6.7% to 4.7% in the control arm (adjusted intervention effect=62%
- 365 [95% CI: 22%, 80%]) (**Table 3**). The impact of MDA differed between the <10 and ≥10 years
- age group (adjusted intervention effect=76% [95% CI: 42%, 90%] versus 51% [95%% CI: -14%,
- 79%]), but this finding did not reach statistical significance (p<sub>interaction</sub>=0·17). By PCR, parasite
- prevalence decreased between 2020 and 2021, from 17.9% to 4.5% in the intervention arm and
- 19.9% to 8.3% in the control arm (adjusted intervention effect=47% [95% CI: 3%, 71%]). The
- effect of MDA differed between the <10 and  $\ge 10$  years age groups: adjusted intervention
- effect=71% [95% CI: 35%, 87%] and 33% [95% CI: -27%, 65%], respectively (p<sub>interaction</sub>=0.050).
- The impact of MDA on microscopy- or PCR-confirmed parasite prevalence did not significantly
- differ between low and moderate transmission settings (p<sub>interaction</sub> for microscopy-confirmed
- prevalence=0.73, p<sub>interaction</sub> for PCR-confirmed prevalence=0.73) (**Table 3**).
- In both passive and active pharmacovigilance systems, the frequency of AEs reduced with each
- 376 subsequent cycle and no serious adverse events (SAEs) were detected in either arm (**Appendix**
- **5; Table 4**). Through passive surveillance, 129 AEs were observed in 67/20 887 (0.003%)
- participants of the intervention arm and four AEs were observed in 2/9524 (0.0002%)
- participants of the control arm; all were mild (**Appendix 5**). Both the frequency and proportion
- of participants who experienced an AE were higher in the intervention arm compared to the
- 381 control arm (p<0.0001). The most common AEs found in the intervention arm were
- gastrointestinal issues (45.7%), headaches (25.6%), and fever (17.1%).

- Through active surveillance, more participants of the intervention arm reported an AE compared
- to the control arm (13.7% versus 9.4%; p<0.0001) (**Table 4**). Among children aged <10 years,
- the proportion of reported AEs were similar between arms (10.1% versus 9.4%; p=0.57). In the
- intervention arm, the most common AEs were gastrointestinal issues (41.2%), fever (22.7%), and
- headaches (11.8%). Of the 498 AEs reported in the intervention arm, 64.1% were mild, 32.9%
- were moderate, and 3.0% were severe. Severe AEs included fever (n=7), headache (n=4),
- drowsiness (n=1), vomiting (n=1), diarrhoea (n=1), and loss of appetite (n=1). All AEs appeared
- three hours after drug intake, resolved within 72 hours, and did not require hospitalization. No
- cases of anaemia were found through either passive or active surveillance.
- 392 Of the 597 PCR-positive samples collected from surveys, 433 were successfully genotyped to
- determine molecular markers of antimalarial resistance (Appendix 6). Mutations associated with
- intermediate resistance to SP (PfDHFR N51I, C59R, S108N and PfDHPS A437G) were seen at
- high proportions (range: 58%–100%). PfDHFR I164L was seen at proportions of 2%–12%.
- None of the studied mutations differed in proportions between arms or time periods. There was
- no evidence of PfDHPS K540E, PfDHPS A581G, or PfK13 C580Y mutations.

# **Discussion**

- We conducted a cluster randomised controlled trial evaluating the safety, coverage, and short-
- 400 term effectiveness of three rounds of MDA with dihydroartemisinin-piperaquine + single low-
- dose primaquine in a low-to-moderate transmission setting of Senegal where malaria control
- interventions were scaled-up through pyrethroid-PBO bednet distribution, three monthly SMC
- 403 cycles, and expansion of year-round proactive community case management of malaria. During
- 404 the trial intervention year, malaria incidence and parasite prevalence reduced in both arms, likely
- due in part to pyrethroid-PBO bednet distribution. In intervention villages, MDA was associated
- 406 with a 55% and 62% reduction in malaria incidence and microscopy-confirmed parasite
- prevalence. Subgroup analyses showed that MDA had a substantial impact on incidence and
- 408 parasite prevalence in those <10 and  $\ge 10$  years of age and in both low and moderate transmission
- settings. Overall, MDA was well-tolerated; most AEs were mild or moderate and no cases of
- anaemia or SAEs were observed.
- While the trial was not designed to separately estimate MDA's effect on transmission versus its
- direct, prophylactic effect, there was some evidence to suggest that MDA indirectly affected
- 413 transmission. First, subgroup analyses demonstrated that among children under ten, MDA was
- associated with a 46% reduction in incidence as compared to children under ten in the control
- arm who received SMC. We expect that this reduction is unlikely by differences in the
- prophylactic effects of these drugs given we expect dihydroartemisinin-piperaquine and
- sulfadoxine-pyrimethamine + amodiaquine to have similar protective efficacies, <sup>11</sup> MDA covered
- less of the transmission season, and MDA had slightly lower coverage than SMC in under tens.
- Moreover, MDA's impact on parasite prevalence further supports this reasoning, given the
- 420 endline survey was conducted more than two months after the last cycle of drug administration
- when the prophylactic effects of both MDA and SMC drugs would have waned.
- Our study has several important findings/caveats. First, our monthly incidence analyses (**Figure**
- 423 4) revealed that SMC should have started one month later and both chemoprevention campaigns

- should have been extended to four cycles to cover the entire transmission season. If this had this
- been done, the impact of MDA in children under tens might not have been as substantial.
- Second, our findings may not be generalisable to most settings deploying SMC where the
- malaria burden is mostly moderate-to-high. While our study found MDA was associated with
- reductions in malaria burden and short-term transmission, evidence of its sustained benefit and
- 429 cost-effectiveness is needed before considering MDA as an intermediate intervention to
- 430 accelerate malaria elimination.
- The WHO currently recommends MDA for transmission reduction in very low-to-low
- transmission settings (i.e., parasite prevalence of <10% or incidence <250 cases/1000
- 433 population). This recommendation is based on evidence from eight cluster randomised controlled
- 434 trials which found MDA can have a substantial, but short-term impact in these settings. 1,21,22
- However, MDA is not recommended for transmission reduction in moderate-to-high
- transmission settings, based on evidence from two cluster randomised trials and two non-
- randomized studies which did not show significant short- or long-term impacts on prevalence or
- incidence. Our study provides new evidence indicating MDA may have a short-term impact on
- transmission in both low and moderate transmission strata. Our findings are consistent with a
- recent trial conducted in a moderate transmission setting of The Gambia<sup>23</sup> which demonstrated a
- 70% reduction in the odds of PCR-confirmed infection two months after the last MDA cycle.
- Evidence from these two studies should be considered when determining future
- recommendations in moderate transmission settings.
- There were several strengths of the study, including our large sample size, rigorous monitoring
- of safety, and achievement of high coverage. By the final MDA cycle, 70% (21/30) of villages
- reached the WHO target for MDA coverage  $(\ge 80\%)^7$ , despite significant operational challenges
- in door-to-door drug administration amidst the peak of the global COVID-19 pandemic. The
- 448 high coverage observed in our study was likely attributable to community acceptance of annual
- SMC campaigns, established infrastructure of community case management, support from key
- administrative and health authorities, and repeated community sensitisation campaigns.
- However, absences were common during MDA cycles (14-21%), especially among adolescents
- 452 and young adults who are generally asymptomatic and known to be important drivers of
- 453 transmission.<sup>24</sup> Thus, in order to sustain gains made, future MDA campaigns will need to
- consider additional strategies to reach these groups in order to prevent malaria importation and
- 455 potential resurgence after MDA.
- Our study had a few limitations. First, as explained earlier, SMC was not optimally timed,
- 457 making it difficult to draw direct comparisons between SMC and MDA for burden reduction in
- 458 children. Second, baseline incidence was likely non-differentially mismeasured in villages where
- 459 DSDOMs were absent at the start of the study (33% of villages). While the stratified
- 460 randomization scheme balanced this factor between arms, this may have biased our effect
- estimates toward the null (see **Appendix 7** for analyses restricted to villages with prior
- 462 PECADOM+). Third, given baseline incidence was likely mismeasured, subgroup analyses by
- baseline malaria incidence were not reported. Fourth, parasitological confirmation of malaria
- incidence relied on RDT which could have resulted in false positives potentially biasing our
- 465 effect estimates toward the null. Fifth, MDA was conducted for only one year and additional
- 466 cycles may have been needed to reach pre-elimination status (i.e., incidence <5 cases/1000

population). Finally, the current analyses only evaluated short-term impact. After discontinuation of MDA, there is potential for malaria to rebound, and analyses of longer-term impact and cost-effectiveness from an additional year of follow-up of these cohorts are forthcoming which will help to determine the sustainability of MDA.

In low-to-moderate malaria transmission settings, where transmission is seasonal and coverage of standard malaria control interventions is high, we demonstrated that three cycles of MDA with dihydroartemisinin-piperaquine + single-low dose primaquine could safely and rapidly reduce malaria burden and potentially have a short-term impact on transmission. However, future work investigating whether the impact of MDA can be sustained, and its cost-effectiveness is needed to inform countries of the potential of MDA as an intervention to accelerate toward elimination.

# **Role of the funding source**

- The study was funded under the US President's Malaria Initiative Impact Malaria Consortium.
- The funders participated in the design of the study and reviewed the manuscript prior to
- submission. The funders had no role in data collection and data analysis. The first authors had
- full access to the study data and final responsibility for the decision to submit the manuscript.

# Acknowledgements

477

482

495

506

- We are grateful to the community of Tambacounda Health District for their participation in the
- study. We thank the health workers, district health staff, the PNLP, and research team at
- 485 Université Iba Der Thiam de Thiès for their contributions in implementing the study and to PMI
- Vectorlink for conducting pyrethroid-PBO bednet distribution and the early village population
- 487 census. We also thank our data safety and monitoring board members Prof Umberto
- 488 D'Alessandro (chair), Prof Jean Guadart, Prof Menno R Smit, Dr Houda Sefiani, and Dr Thomas
- J Peto for their guidance and oversight of the study. We would also like to thank Drs Meera
- 490 Venkatesan, Meghna Desai, and Leah Moriarty for their contributions in the early protocol
- 491 development and study planning, Dr Mame Birame Diouf for his initial coordination and
- 492 strategic engagement of in-country partners, Drs Jean Biyik and Abdoulaye Diop for their
- support in coordinating the pyrethroid-PBO bednet distribution, and Dr Hannah Slater for
- 494 providing the mathematical modelling analysis used for our sample size calculations.

# **Contributions**

- 496 JH conceived of the study and wrote the first draft of the protocol. RG, JLN, MER, AB, KSR,
- 497 JT, EBKC, FB, ST, ID, and ABG contributed to the protocol and approved of the final version.
- 498 EBKC, AD, TG, AS, ST, SG, ACL, ED, ID, OGB, and JLN implemented the study. JLN,
- 499 EBKC, AD, TG, ABG, ST, KSR, MER, MSH, TK, MH, EE, RG, DS, and FB provided
- oversight of the study. ACL conducted laboratory analysis of samples. The statistical analysis
- plan was developed by MSH, PM, AF, MER, AB, EBKC, and JLN and data were analysed by
- 502 AF with XW, MER, AS, and EBKC. MER, EBKC, AF, XW, PM, AB, JH, KSR, MSH, and JLN
- interpreted the results. MER, EBKC, MSH, and JLN wrote the first draft of the manuscript. PM,
- interpreted the results. WEEK, EDICE, WISH, and SEA, whole the first draft of the manuscript. I will
- 504 JH, AF, and KSR provided additional inputs to the writing. All authors reviewed and approved
- 505 the final manuscript before submission.

### **Declaration of interests**

- The study was funded by the US President's Malaria Initiative. MER is supported by the Eunice
- 508 Kennedy Shriver National Institute of Child Health & Human Development of the National
- Institutes of Health (Award Number K99HD111572). JH and ABG receive salary support from
- the US President's Malaria Initiative. The findings and conclusions in this report are those of the
- authors and do not necessarily represent the official position of the National Institutes of Health,
- 512 US Centers of Disease Control and Prevention, and the US Agency for International
- 513 Development.

# Data sharing

- De-identified data may be available upon reasonable request and approval from Principal
- 516 Investigators via a data sharing agreement.


### References

- 518 1. World Health Organization. WHO guidelines for malaria, 3 June 2022: World Health
- 519 Organization, 2022.
- 520 2. SMC Alliance. 53 million children living in 18 countries covered with Seasonal Malaria
- 521 Chemoprevention in 2023. April 5, 2024 2024. https://www.smc-alliance.org/53-million-
- 522 <u>children-living-in-18-countries-covered-with-seasonal-malaria-chemoprevention-in-2023</u>
- 523 (accessed July 17, 2024.
- 524 3. Cairns M, Ceesay SJ, Sagara I, et al. Effectiveness of seasonal malaria chemoprevention
- 525 (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries. *PLoS*
- 526 *Med* 2021; **18**(9): e1003727.
- 527 4. World Health Organization. World Malaria Report 2022. Geneva, Switzerland: World
- Health Organization; 2022.
- 529 5. Newby G, Hwang J, Koita K, et al. Review of mass drug administration for malaria and
- its operational challenges. *Am J Trop Med* 2015; **93**(1): 125.
- 531 6. Shah MP, Hwang J, Choi L, Lindblade KA, Kachur SP, Desai M. Mass drug
- administration for malaria. *The Cochrane Database of Systematic Reviews* 2021; **2021**(9).
- 533 7. World Health Organization. Mass drug administration for falciparum malaria: a practical
- 534 field manual. 2017.
- 535 8. Cairns ME, Sagara I, Zongo I, et al. Evaluation of seasonal malaria chemoprevention in
- two areas of intense seasonal malaria transmission: secondary analysis of a household-
- randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District,
- 538 Mali. *PLoS Med* 2020; **17**(8): e1003214.
- 539 9. NDiaye J, Cissé B, Ba E, et al. Safety of seasonal malaria chemoprevention (SMC) with
- sulfadoxine-pyrimethamine plus amodiaquine when delivered to children under 10 years of age
- by district health services in Senegal: results from a stepped-wedge cluster randomized trial.
- 542 *PLoS One* 2016; **11**(10): e0162563.
- 543 10. Gutman J, Kovacs S, Dorsey G, Stergachis A, Ter Kuile FO. Safety, tolerability, and
- efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of
- malaria: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; **17**(2): 184-93.
- 546 11. Zongo I, Milligan P, Compaore YD, et al. Randomized noninferiority trial of
- 547 dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for
- seasonal malaria chemoprevention in Burkina Faso. *Antimicrob Agents Chemother* 2015; **59**(8):
- 549 4387-96.
- 550 12. Dicko A, Roh ME, Diawara H, et al. Efficacy and safety of primaquine and methylene
- blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind,
- randomised controlled trial. *Lancet Infect Dis* 2018; **18**(6): 627-39.
- 553 13. Sawa P, Shekalaghe SA, Drakeley CJ, et al. Malaria transmission after artemether-
- lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. *J Infect Dis* 2013; **207**(11):
- 555 1637-45.
- World Health Organization. Policy brief on single-dose primaquine as a gametocytocide
- in Plasmodium falciparum malaria: World Health Organization, 2015.
- 558 15. Stepniewska K, Humphreys GS, Gonçalves BP, et al. Efficacy of single-dose primaquine
- with artemisinin combination therapy on Plasmodium falciparum gametocytes and transmission:
- an individual patient meta-analysis. J Infect Dis 2022; 225(7): 1215-26.

- 561 16. Eisele TP, Bennett A, Silumbe K, et al. Short-term impact of mass drug administration
- with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-
- randomized controlled trial. *J Infect Dis* 2016; **214**(12): 1831-9.
- 564 17. Griffin JT. The interaction between seasonality and pulsed interventions against malaria
- in their effects on the reproduction number. *PLoS Comput Biol* 2015; **11**(1): e1004057.
- 566 18. Amoah LE, Opong A, Ayanful-Torgby R, Abankwa J, Acquah FK. Prevalence of G6PD
- deficiency and Plasmodium falciparum parasites in asymptomatic school children living in
- 568 southern Ghana. *Malar J* 2016; **15**(1): 1-8.
- 569 19. Rougemont M, Van Saanen M, Sahli R, Hinrikson HP, Bille J, Jaton K. Detection of four
- 570 Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-
- specific real-time PCR assays. *J Clin Microbiol* 2004; **42**(12): 5636-43.
- 572 20. Chomarat M, Breysse F. Technique d'analyse des courbes de fusion haute résolution
- 573 (FHR) ou High Resolution Melting analysis (HRM) en infectiologie. *Immuno-Anal Biol Spe*
- 574 2011; **26**(4): 207-11.
- 575 21. Schneider ZD, Shah MP, Boily MC, et al. Mass Drug Administration to Reduce Malaria
- 576 Transmission: A Systematic Review and Meta-Analysis. Am J Trop Med 2023: tpmd220766-
- 577 tpmd.
- 578 22. Malaria Policy Advisory Committee. Meeting report of the Evidence Review Group on
- mass drug administration, mass screening and treatment and focal screening and treatment for
- 580 malaria (20–22 April 2015). Geneva, Switzerland, 2015.
- 581 23. Dabira ED, Soumare HM, Conteh B, et al. Mass drug administration of ivermectin and
- 582 dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard
- 583 control interventions: a cluster-randomised controlled trial in The Gambia. Lancet Infect Dis
- 584 2022; **22**(4): 519-28.
- Rek J, Blanken SL, Okoth J, et al. Asymptomatic school-aged children are important
- drivers of malaria transmission in a high endemicity setting in Uganda. *J Infect Dis* 2022; **226**(4):
- 587 708-13.

# 589 **Figures**


Figure 1. Timeline of study activities



Abbreviations: MDA = mass drug administration; PBO = piperonyl butoxide; PECADOM+ = Prise en Charge à Domicile Plus (i.e., proactive community case management of malaria); SMC = seasonal malaria chemoprevention

# Figure 2. Trial profile

590




Abbreviations: HP = health post; MDA = mass drug administration; PECADOM+ = Prise en Charge à Domicile Plus (i.e., proactive community case management of malaria); SMC = seasonal malaria chemoprevention

**Figure 3.** Graphical representation of village-level monthly incidence of symptomatic malaria during the intervention implementation year by intervention group (A) and stratified by age group (B), and baseline transmission intensity (C).

591

592593



Abbreviations: MDA = mass drug administration; SMC = seasonal malaria chemoprevention
Monthly incidence rates and corresponding 95% confidence intervals, represented by points and bars, respectively, were calculated using a random effects
Poisson model with village-level random intercepts to account for clustered observations.

#### **Tables** 594

595

# Table 1. Trial profile

Characteristics	Total	Intervention (MDA)	Control
Village-level <sup>1</sup>			
Number of clusters (villages)	60	30	30
Villages by health post, n (%)			
Bohe	9 (15%)	6 (20%)	3 (10%)
Dar Salam	2 (3%)	1 (3%)	1 (3%)
Dawadi	14 (23%)	6 (20%)	8 (27%)
Koussanar	9 (15%)	5 (17%)	4 (13%)
Missirah	6 (10%)	2 (7%)	4 (13%)
Neteboulou	5 (8%)	2 (7%)	3 (10%)
Sinthiou Maleme	15 (25%)	8 (27%)	7 (23%)
Presence of DSDOM prior to the study, n (%)			
No	20 (33%)	10 (33%)	10 (33%)
Yes	40 (67%)	20 (67%)	20 (67%)
Distance to health post in km, mean (SD)	14.8 (8.4)	14.9 (8.6)	14.6 (8.3)
Population size in 2019 <sup>2</sup> , mean (SD)	322 (168)	330 (170)	315 (168)
Population size <10 years of age in 2019 <sup>2</sup> , mean (SD)	119 (62)	120 (63)	117 (62)
% Population <10 years of age in 2019, mean (SD)	37% (5)	36% (4)	37% (6)
Baseline microscopy prevalence (%), mean (SD)	8% (8)	7% (9)	9% (8)
Individual-level Characteristics from Baseline Survey	, n (%)		
Participant age in years			•
<10 years of age	783 (33%)	373 (32%)	410 (35%)
≥10 years of age	1578 (67%)	809 (68%)	769 (65%)
Participant sex			
Male	1180 (50%)	576 (49%)	604 (51%)
Female	1182 (50%)	607 (51%)	575 (49%)
Slept away from home in the past 15 days			
Yes	459 (20%)	245 (21%)	214 (19%)
No	1846 (80%)	910 (79%)	936 (81%)
Type of bed net used			
None	37 (2%)	28 (2%)	9 (1%)
Pyrethroid-PBO ITN	2282 (98%)	1131 (96%)	1151 (99%)
Non-pyrethroid-PBO ITN	21 (1%)	20 (2%)	1 (0.1%)
Received the most recent cycle of SMC? <sup>3</sup>	` '	, ,	,
No	169 (20%)	94 (23%)	75 (17%)
Yes	687 (81%)	316 (77%)	371 (83%)
Completed all three cycles of SMC in 2020? <sup>3</sup>	. ,		` ′
No	248 (29%)	128 (31%)	120 (27%)
Yes	610 (71%)	284 (69%)	326 (73%)

Abbreviations: ITN = insecticide-treated net; MDA = mass drug administration; PBO = piperonyl butoxide; SD = standard deviation; SMC = seasonal malaria chemoprevention

<sup>&</sup>lt;sup>1</sup> Village-level variables used in constrained randomization scheme.

<sup>&</sup>lt;sup>2</sup> Incidence estimates provided by Tambacounda Regional District Office.
<sup>3</sup> Assessed only among children <10 years of age.

**Table 2.** RDT-confirmed malaria incidence and intervention effectiveness estimates during peak transmission season (July-December)

	Average incidence per 1,000 (events / population)				Intervention effect,		
Study outcomes	Intervention (MDA)		Control		1-ratio of IRRs [95% CI] <sup>1</sup>		
	2020	2021	2020	2021	Unadjusted	Adjusted <sup>2</sup>	
Primary outcome							
Incidence among all ages	181 (2067/10745)	93 (924/10745)	204 (1883/9641)	173 (1751/9641)	52% [21%, 71%]	55% [28%, 72%]	
<10 years old	133 (514/4091)	84 (287/4091)	154 (515/3598)	120 (463/3598)	43% [3%, 66%]	46% [10%, 67%]	
≥10 years and older	213 (1553/6637)	100 (633/6637)	236 (1368/5991)	206 (1287/5991)	55% [27%, 73%]	58% [33%, 74%]	
Subgroup analyses							
Among children <10 years	of age						
<5 years of age	102 (163/1939)	69 (115/1939)	133 (208/1723)	93 (166/1723)	29% [-35%, 62%]	31% [-25%, 62%]	
5 to <10 years of age	85 (351/2152	61 (172/2152)	118 (307/1875	85 (297/1875)	43% [-4%, 69%]	45% [4%, 68%]	
Baseline transmission inter	nsity <sup>3</sup>						
Low (<10%)	172 (1508/8316)	83 (658/8316)	228 (1385/6463)	171 (1085/6463)	53% [25%, 71%]	55% [31%, 71%]	
Moderate (≥10%)	214 (559/2429)	125 (266/2429)	148 (498/3178)	178 (666/3178)	49% [-48%, 82%]	52% [-19%, 81%]	

Abbreviations: IRR = incidence rate ratio; MDA = mass drug administration

<sup>&</sup>lt;sup>1</sup> Intervention effect estimated using mixed effects Poisson regression with village-level random intercepts.

<sup>&</sup>lt;sup>2</sup> Adjusted for DSDOM at baseline, village population size of children <10 years of age, distance from health post, baseline parasite prevalence by microscopy, and village population size in 2019, and presence of DSDOM at time of case detection.

<sup>&</sup>lt;sup>3</sup> Transmission intensity was defined as baseline village-level microscopy-confirmed parasite prevalence of <10% for "Low" transmission clusters and ≥10% for "Moderate" transmission clusters. 23 clusters from the intervention arm and 21 clusters from the control arm contributed to "Low" category; 7 clusters in intervention arm and 9 clusters in control arm contributed to "Moderate" category.

597 **Table 3.** Secondary outcomes of parasite prevalence.

	Mean prevalence, % [95% CI] <sup>1</sup>				Intervention effect,	
Outcomes	Interven	Intervention (MDA)		ontrol	1-ratio of PRs [95% CI] <sup>1</sup>	
	2020	2021	2020	2021	Unadjusted	Adjusted <sup>2</sup>
Microscopy-detected infec	ctions				-	-
All ages	6·1% [2·8%, 9·4%]	1·8% [0·8%, 2·9%]	6·7% [4·0%, 9·4%]	4·7% [2·5%, 6·9%]	61% [21%, 81%]	62% [22%, 80%]
< 10 years old	8·2% [2·7%, 13·7%]	1·3% [0·2%, 2·4%]	7·3% [3·1%, 11·6%]	4·5% [2·0%, 7·0%]	76% [41%, 90%]	76% [42%, 90%]
$\geq$ 10 years and older	5·1% [2·6%, 7·7%]	2·2% [0·7%, 3·6%]	6·4% [3·9%, 8·8%]	4·8% [1·8%, 7·9%]	50% [-16%, 79%]	51% [-14%, 79%]
Baseline transmission inten	sity <sup>3</sup>					
Low (<10%)	2·6% [1·3%, 3·9%]	1.0% [0.2%, 1.8%]	3·4% [2·1%, 4·8%]	4·3% [1·4%, 7·2%]	63% [-1%, 86%]	62% [0%, 86%]
Moderate (≥10%)	18·8% [9·4%, 28·2%]	5·0% [2·1%, 7·8%]	17·1% [12·5%, 21·8%]	6·0% [3·4%, 8·6%]	54% [18%, 73%]	56% [22%, 75%]
PCR-detected infections						
All ages	17·9% [11·3%, 24·4%]	4·5% [2·5%, 6·4%]	19·9% [11·8%, 28·1%]	8·3% [4·8%, 11·7%]	46% [-3%, 70%]	47% [3%, 71%]
< 10 years old	18·6% [10·9%, 26·4%]	2·3% [0·6%, 3·9%]	19·6% [9·9%, 29·4%]	5·1% [2·2%, 8·0%]	71% [34%, 87%]	71% [35%, 87%]
$\geq$ 10 years and older	17·5% [11·0%, 24·0%]	5·8% [2·9%, 8·6%]	20·1% [11·7%, 28·5%]	10·2% [5·2%, 15·3%]	33% [-27%, 64%]	33% [-27%, 65%]
Baseline transmission inten	sity <sup>3</sup>					
Low (<10%)	14·0% [7·9%, 20·1%]	3·0% [1·0%, 5·0%]	14·3% [6·3%, 22·3%]	4·7% [2·4%, 6·9%]	48% [-4%, 74%]	47% [-7%, 74%]
Moderate (≥10%)	32·0% [11·4%, 52·5%]	9.9% [6·1%, 13·7%]	38·0% [21·7%, 54·4%]	18·7% [12·2%, 25·3%]	37% [2%, 59%]	40% [9%, 60%]

Abbreviations: MDA = mass drug administration; PCR = polymerase chain reaction; PR = prevalence ratio

<sup>&</sup>lt;sup>1</sup> Intervention effect estimated using Poisson regression with robust standard errors. Survey weights incorporated to account for two-stage sampling design (by household and household size).

<sup>&</sup>lt;sup>2</sup> Adjusted for variables included in constrained randomisation: presence of DSDOM at baseline, village population size of children <10 years of age, distance from health post, and village population size in 2019.

<sup>&</sup>lt;sup>3</sup> Transmission intensity was defined as baseline village-level microscopy-confirmed parasite prevalence of <10% for "Low" transmission clusters and ≥10% for "Moderate" transmission clusters. 23 clusters from the intervention arm and 21 clusters from the control arm contributed to "Low" category; 7 clusters in intervention arm and 9 clusters in control arm contributed to "Moderate" category.

**Table 4.** Safety outcomes monitored through active surveillance

Active Surveillance	Intervention (MDA)	Control (SMC)	p-value <sup>1</sup>
Among all participants surveyed			
Participants with any AE, n/N (%)			
All cycles	260/1903 (13.7%)	152/1616 (9.4%)	< 0.0001
First cycle	124/619 (20.0%)	93/569 (16.3%)	0.10
Second cycle	94/628 (15.0%)	51/563 (9.1%)	0.002
Third cycle	42/656 (6.4%)	8/484 (1.7%)	< 0.0001
Frequency of adverse events, n	,	,	
All cycles	498	310	
First cycle	229	175	
Second cycle	181	119	
Third cycle	88	16	
Most common adverse events, n/N (%)			
Gastrointestinal issues <sup>2</sup>	205/498 (41.2%)	144/310 (46.5%)	0.16
Fever	113/498 (22.7%)	109/310 (35.2%)	<0.001
Headaches	59/498 (11.8%)	20/310 (6.5%)	0.017
Drowsiness	26/498 (5.2%)	8/310 (2.6%)	0.102
Other	95/498 (19.1%)	29/310 (9.4%)	<0.001
Severity of AEs, n/N (%)	75/ 170 (17.170)	25/510 (5.170)	<b>VO 001</b>
Mild	319/498 (64·1%)	178/310 (57.4%)	0.059
Moderate	164/498 (32.9%)	118/310 (38·1%)	0.035
Severe	15/498 (3.0%)	14/310 (4.5%)	0.26
Any serious AE, n/N (%)	0/498 (0%)	0/310 (0%)	
Among children <10 years of age	0/470 (070)	0/310 (0/0)	
Participants with any AE, n/N (%)			
All cycles	95/941 (10 10/)	145/1544 (0.40/)	0.57
•	85/841 (10.1%)	145/1544 (9.4%)	
First cycle	36/259 (13.9%)	90/547 (16.5%)	0.35
Second cycle	33/271 (12·2%)	47/529 (8.9%)	0.14
Third cycle	16/311 (5·1%)	8/468 (1.7%)	0.007
Frequency of adverse events, n	177	20.6	
All cycles	176	296	
First cycle	68	170	
Second cycle	67	110	
Third cycle	41	16	
Most common adverse events, n/N (%)			
Gastrointestinal issues <sup>2</sup>	87/176 (49·4%)	136/296 (45.9%)	0.523
Fever	50/176 (28·4%)	106/296 (35.8%)	0.121
Headache	10/176 (5.7%)	19/296 (6.4%)	0.901
Drowsiness	2/176 (1·1%)	8/296 (2.7%)	0.334
Other	27/176 (15.3%)	27/296 (9.1%)	0.0057
Severity of AEs, n/N (%)			
Mild	102/176 (58.0%)	169/296 (57-1%)	0.86
Moderate	69/176 (39·2%)	115/296 (38.9%)	0.94
Severe	5/176 (2.8%)	12/296 (4.1%)	0.49
Any serious AE, n/N (%)	0/176 (0%)	0/296 (0%)	

Abbreviations: AE = adverse event

P-value computed using Chi-squared test or Fisher's exact test (if frequency of any cell value was <5)

<sup>&</sup>lt;sup>2</sup> Defined as one of the following AEs: nausea, vomiting, diarrhoea, abdominal pain, or loss of appetite.